Kezdőlap・Részvénylista・MacroGenics Inc

MacroGenics Inc

Lezárt

SzektorEgészségügy

4.01 -1.96

Vétel Eladás

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

4.03

Maximum

4.09

Fő mutatók
By Trading Economics
Bevétel	56M 20M
Értékesítés	12M 33M
Egy részvényre jutó nyereség	-0.27
Profit margin	59.439
Munkavállalók	293
EBITDA	16M -14M

Ajánlások
By TipRanks
Ajánlások	Vétel
12 hónapos előrejelzés	+70.73% upside

Osztalékok
By Acuity
Következő eredményjelentés	2026. nov. 10.

Piaci statisztika
By TradingEconomics
Piaci kapitalizáció	-702K 259M
Előző nyitás	5.97
Előző zárás	4.01

Hangulat hírek alapján

By Acuity

29%

71%

84 / 340 Rangsor szerint Healthcare

MacroGenics Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 20. 20:06 UTC

MacroGenics shares are lower today, pulling back from earlier session highs amid rising crude oil prices and increased U.S. Treasury yields.

2026. aug. 19. 21:01 UTC

MacroGenics Inc shares are lower in after-market trading, continuing a decline since Wednesday's close, with no specific news identified to explain the movement.

2026. aug. 18. 19:46 UTC

MacroGenics Inc. shares are gaining during Tuesday's session, despite earlier pulling back from a session high amid rising Treasury yields and inflation concerns.

2026. aug. 17. 19:51 UTC

MacroGenics Inc shares are lower today amid unusual volatility, having hit a session low before a brief recovery. No specific news was identified.

2026. aug. 14. 19:21 UTC

Shares of MacroGenics Inc. are lower today amid cautious investor sentiment following a drop in U.S. retail sales, impacting expectations for Federal Reserve interest rate hikes.

2026. aug. 13. 21:01 UTC

News

MacroGenics shares declined after reporting Q2 2026 results, which included a workforce reduction and a pro forma cash position of $327 million.

2026. aug. 12. 19:46 UTC

Social Media

MacroGenics Inc received a $10 million milestone payment, boosting investor sentiment and contributing to shares trading higher during Wednesday's session.

2026. aug. 11. 22:26 UTC

News

MacroGenics shares rise after Gilead Sciences exercises licensing option, triggering a $10 million payment and potential for $1.6 billion in future milestones.

2026. aug. 4. 19:46 UTC

MacroGenics shares are lower today, retracing from a session high amid a broader market decline linked to falling crude oil prices.

2026. júl. 31. 20:06 UTC

MacroGenics Inc. shares are lower today amid rising U.S. Treasury yields and inflation concerns, continuing a downward trend since Thursday's close.

2026. júl. 29. 20:09 UTC

MacroGenics Inc shares are lower today, continuing a downward trend since Tuesday's close. The stock showed early gains before sharply reversing course.

2026. júl. 28. 17:03 UTC

MacroGenics Inc shares are lower today amid broader market volatility. The stock remains near the lower end of its one-month range.

2026. júl. 27. 20:01 UTC

News

MacroGenics shares are higher as analysts remain optimistic about MGC026's potential, supported by a strong cash runway projected until 2028.

2026. júl. 24. 20:01 UTC

MacroGenics Inc shares are declining amid broader biotechnology sector weakness, marking four consecutive sessions of losses with no specific company news identified.

2026. júl. 22. 19:51 UTC

MacroGenics Inc is trading lower today, breaking a trend of higher closes. Broader market sentiment is cautious amid rising crude oil prices and geopolitical tensions.

2026. júl. 21. 19:06 UTC

MacroGenics Inc shares are higher, supported by optimism in the semiconductor sector and potential price increases from TSMC by 2027.

Társak összehasonlítása

Árváltozás

MacroGenics Inc Előrejelzés

Célár

By TipRanks

70.73% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 7 USD 70.73%

Magas 11 USD

Alacsony 4 USD

4 Wall Street elemző 12 hónapos célárain alapulva a(z)MacroGenics Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Vétel

4 ratings

Vétel

Tartás

Eladás

4 Wall Street elemző célárain alapulva a(z)MacroGenics Inc termékhez az elmúlt 3 hónapban.

Hangulat

By Acuity

84 / 340 Rangsor szerint Egészségügy

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

Rólunk MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.